TOKYO -- A provision to let Takeda Pharmaceutical claw back executive pay after a major loss or false accounting drew majority support from shareholders even while failing to pass, in a sign of the scrutiny Japan's top drugmaker faces over its roughly $60 billion purchase of Irish peer Shire.
The vote on the shareholder-initiated proposal was disclosed Tuesday in Takeda's report on last week's general meeting.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
to learn how you can update your cookie settings.